gabapentin and MS (Multiple Sclerosis) studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

Excerpt	Relevance	Reference
"A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis."	9.14	Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010)
"To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis."	9.09	Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000)
"At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis."	9.08	Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997)
"The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine."	7.73	The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006)
"We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)."	7.70	An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998)
"This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy."	7.70	Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998)
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy."	6.68	Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997)
"A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis."	5.14	Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010)
"To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis."	5.09	Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000)
"At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis."	5.08	Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997)
"The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine."	3.73	The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006)
"A 40-year-old patient with acquired horizontal and vertical nystagmus and severe oscillopsia secondary to multiple sclerosis had combined treatment with gabapentin and a vertical Kestenbaum-type procedure."	3.71	Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. ( Constantinescu, CS; Gottlob, I; Jain, S; Proudlock, F, 2002)
"We conducted an open-label trial of gabapentin (GBP) as therapy for paroxysmal symptoms (PS) in 21 MS patients, including trigeminal neuralgia (6 patients), painful tonic spasms (11), dysesthetic or paresthetic symptoms (3) and ocular ataxia (1)."	3.70	An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. ( Capello, E; Inglese, M; Lunardi, GL; Mancardi, GL; Messmer Uccelli, M; Solaro, C; Uccelli, A, 1998)
"This report describes the effectiveness of gabapentin, a recently approved anticonvulsant, in seven patients with MS experiencing trigeminal neuralgia refractory to treatment with conventional medical therapy."	3.70	Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. ( Khan, OA, 1998)
"Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy."	2.68	Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997)
"Mycophenolic acid was detected in all cats."	2.61	( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs."	2.53	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016)
"The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol."	2.48	[Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012)
"Among the more common symptoms is spasticity."	2.41	Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001)
"Treatment of spasticity includes oral and intrathecal anti-spastic drugs, muscle injections with relaxant agents, physical therapy, electrical and magnetic stimulation and peripheral nerve stimulation, alone or in various combinations."	1.56	Italian consensus on treatment of spasticity in multiple sclerosis. ( Centonze, D; Comi, G; Leocani, L; Otero-Romero, S; Solari, A, 2020)
"Although mouse models of experimental autoimmune encephalomyelitis (EAE) have provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe motor impairments confound quantitative assessment of pain behaviors over the disease course."	1.40	Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014)
"Acquired pendular nystagmus (APN) occurs with multiple sclerosis (MS) and oculopalatal tremor (OPT); distinct features of the nystagmus have led to the development of separate models for their pathogenesis."	1.37	Pharmacological tests of hypotheses for acquired pendular nystagmus. ( Leigh, RJ; Optican, LM; Shaikh, AG; Thurtell, MJ, 2011)
"Carbamazepine (CBZ) was prescribed in 36 patients, with adverse effects reported in 20 cases, of which 12 mimicked a relapse."	1.33	Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005)
"Acquired Pendular Nystagmus (APN) may cause distressing visual symptoms in patients who are already suffering a severe general disease."	1.31	Improvement of acquired pendular nystagmus by gabapentin: case report. ( Fabre, K; Smet-Dieleman, H; Zeyen, T, 2001)

Research

Studies (29)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (24.14)	18.2507
2000's	12 (41.38)	29.6817
2010's	9 (31.03)	24.3611
2020's	1 (3.45)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

7 (24.14)

18.2507

2000's

12 (41.38)

29.6817

2010's

9 (31.03)

24.3611

2020's

1 (3.45)

2.80

Authors

Authors	Studies
Bobenko, AI	1
Heller, S	1
Schmitt, N	1
Cherdtrakulkiat, R	1
Lawung, R	1
Nabu, S	1
Tantimavanich, S	1
Sinthupoom, N	1
Prachayasittikul, S	1
Prachayasittikul, V	1
Zhang, B	1
Wu, C	1
Zhang, Z	2
Yan, K	1
Li, C	2
Li, Y	4
Li, L	3
Zheng, C	1
Xiao, Y	1
He, D	1
Zhao, F	1
Su, JF	1
Lun, SM	1
Hou, YJ	1
Duan, LJ	1
Wang, NC	1
Shen, FF	1
Zhang, YW	1
Gao, ZW	1
Li, J	5
Du, XJ	1
Zhou, FY	1
Yin, Z	1
Zhu, J	2
Yan, D	1
Lou, H	1
Yu, H	1
Feng, C	1
Wang, Z	1
Wang, Y	4
Hu, X	1
Li, Z	2
Shen, Y	1
Hu, D	1
Chen, H	1
Wu, X	1
Duan, Y	1
Zhi, D	1
Zou, M	2
Zhao, Z	1
Zhang, X	2
Yang, X	2
Zhang, J	2
Wang, H	1
Popović, KJ	1
Popović, DJ	1
Miljković, D	1
Lalošević, D	1
Čapo, I	1
Popović, JK	1
Liu, M	1
Song, H	2
Xing, Z	1
Lu, G	1
Chen, D	1
Valentini, AM	1
Di Pinto, F	1
Coletta, S	1
Guerra, V	1
Armentano, R	1
Caruso, ML	1
Gong, J	1
Wang, N	1
Bian, L	1
Wang, M	1
Ye, M	1
Wen, N	1
Fu, M	1
Fan, W	1
Meng, Y	1
Dong, G	1
Lin, XH	1
Liu, HH	1
Gao, DM	1
Cui, JF	1
Ren, ZG	1
Chen, RX	1
Önal, B	1
Özen, D	1
Demir, B	1
Akkan, AG	1
Özyazgan, S	1
Payette, G	1
Geoffroy, V	1
Martineau, C	1
Villemur, R	1
Jameel, T	1
Baig, M	1
Gazzaz, ZJ	1
Tashkandi, JM	1
Al Alhareth, NS	1
Khan, SA	1
Butt, NS	1
Wang, J	2
Geng, Y	1
Zhang, Y	3
Wang, X	2
Liu, J	2
Basit, A	1
Miao, T	1
Liu, W	1
Jiang, W	1
Yu, ZY	1
Wu, L	2
Qu, B	1
Sun, JX	1
Cai, AL	1
Xie, LM	1
Groeneveld, J	1
Ho, SL	1
Mackensen, A	1
Mohtadi, M	1
Laepple, T	1
Genovesi, S	1
Nava, E	1
Bartolucci, C	1
Severi, S	1
Vincenti, A	1
Contaldo, G	1
Bigatti, G	1
Ciurlino, D	1
Bertoli, SV	1
Slovak, JE	1
Hwang, JK	1
Rivera, SM	1
Villarino, NF	1
Li, S	1
Cao, G	1
Ling, M	1
Ji, J	1
Zhao, D	1
Sha, Y	1
Gao, X	1
Liang, C	2
Guo, Q	1
Zhou, C	1
Ma, Z	1
Xu, J	1
Wang, C	1
Zhao, W	1
Xia, X	1
Jiang, Y	1
Peng, J	1
Jia, Z	1
Li, F	1
Chen, X	2
Mo, J	1
Zhang, S	2
Li, X	1
Huang, T	1
Zhu, Q	1
Wang, S	1
Ge, RS	1
Fortunato, G	1
Lin, J	2
Agarwal, PK	1
Kohen, A	1
Singh, P	1
Cheatum, CM	1
Zhu, D	1
Hayman, A	1
Kebede, B	1
Stewart, I	1
Chen, G	1
Frew, R	1
Guo, X	1
Gong, Q	1
Borowiec, J	1
Han, S	1
Zhang, M	1
Willis, M	1
Kreouzis, T	1
Yu, K	1
Chirvony, VS	1
Sekerbayev, KS	1
Pérez-Del-Rey, D	1
Martínez-Pastor, JP	1
Palazon, F	1
Boix, PP	1
Taurbayev, TI	1
Sessolo, M	1
Bolink, HJ	1
Lu, M	1
Lan, Y	1
Xiao, J	1
Song, M	1
Chen, C	1
Huang, Q	1
Cao, Y	1
Ho, CT	1
Qi, B	1
Wang, Q	1
Zhang, W	1
Fang, L	1
Xie, CL	1
Chen, R	1
Yang, S	1
Xia, JM	1
Zhang, GY	1
Chen, CH	1
Yang, XW	1
Domenech-Ximenos, B	1
Garza, MS	1
Prat-González, S	1
Sepúlveda-Martínez, Á	1
Crispi, F	1
Perea, RJ	1
Garcia-Alvarez, A	1
Sitges, M	1
Kalumpha, M	1
Guyo, U	1
Zinyama, NP	1
Vakira, FM	1
Nyamunda, BC	1
Varga, M	1
Drácz, L	1
Kolbenheyer, E	1
Varga, F	1
Patai, ÁV	1
Solymosi, N	1
Patai, Á	1
Kiss, J	1
Gaál, V	1
Nyul, Z	1
Mosdósi, B	1
Valdez, M	1
Moosavi, L	1
Heidari, A	1
Novakovic-Agopian, T	1
Kornblith, E	1
Abrams, G	1
McQuaid, JR	1
Posecion, L	1
Burciaga, J	1
D'Esposito, M	1
Chen, AJW	1
Samy El Gendy, NM	1
Wesolowska, P	1
Georg, D	1
Lechner, W	1
Kazantsev, P	1
Bokulic, T	1
Tedgren, AC	1
Adolfsson, E	1
Campos, AM	1
Alves, VGL	1
Suming, L	1
Hao, W	1
Ekendahl, D	1
Koniarova, I	1
Bulski, W	1
Chelminski, K	1
Samper, JLA	1
Vinatha, SP	1
Rakshit, S	1
Siri, S	1
Tomsejm, M	1
Tenhunen, M	1
Povall, J	1
Kry, SF	1
Followill, DS	1
Thwaites, DI	1
Izewska, J	1
Kang, JH	1
Yoon, Y	1
Song, J	1
Van de Winckel, A	1
Gauthier, L	1
Chao, CT	1
Lee, YH	1
Li, CM	1
Han, DS	1
Huang, JW	1
Huang, KC	1
Ni, L	1
Güttinger, R	1
Triana, CA	1
Spingler, B	1
Baldridge, KK	1
Patzke, GR	1
Shen, X	1
Wang, B	1
Xie, S	1
Deng, W	1
Wu, D	1
Zhang, Q	1
Voskamp, BJ	1
Peelen, MJCS	1
Ravelli, ACJ	1
van der Lee, R	1
Mol, BWJ	1
Pajkrt, E	1
Ganzevoort, W	1
Kazemier, BM	1
Tibrewala, R	1
Bahroos, E	1
Mehrabian, H	1
Foreman, SC	1
Link, TM	1
Pedoia, V	1
Majumdar, S	1
Jablonski, CL	1
Leonard, C	1
Salo, P	1
Krawetz, RJ	1
Yoon, N	1
Hong, SN	1
Cho, JG	1
Jeong, HK	1
Lee, KH	1
Park, HW	1
Barman, S	1
Konai, MM	1
Samaddar, S	1
Haldar, J	1
Mohamed, HSH	1
Li, CF	1
Hu, ZY	1
Deng, Z	1
Chen, LH	1
Su, BL	1
Chu, K	1
Liu, YP	1
Li, YB	1
Zhang, H	1
Xu, C	1
Zou, Z	1
Wu, Z	1
Xia, Y	1
Zhao, P	1
Wang, HT	1
de Biase, S	1
Pellitteri, G	1
Gigli, GL	1
Valente, M	1
Comi, G	2
Solari, A	1
Leocani, L	1
Centonze, D	1
Otero-Romero, S	2
Redon, S	1
Graillon, N	1
Régis, J	1
Donnet, A	1
Khan, N	1
Woodruff, TM	1
Smith, MT	1
Trojano, M	1
Sastre-Garriga, J	1
Hartung, HP	1
Soelberg Sørensen, P	1
Thompson, AJ	1
Vermersch, P	1
Gold, R	1
Montalban, X	1
Starck, M	1
Albrecht, H	1
Pöllmann, W	1
Dieterich, M	1
Straube, A	1
Bittner, S	1
Höhn, K	1
Göbel, K	1
Kleinschnitz, C	1
Wiendl, H	1
Meuth, SG	1
Shaikh, AG	1
Thurtell, MJ	1
Optican, LM	1
Leigh, RJ	2
Heinzlef, O	1
Monteil-Roch, I	1
Jain, S	1
Proudlock, F	1
Constantinescu, CS	1
Gottlob, I	3
Fabre, K	1
Smet-Dieleman, H	1
Zeyen, T	1
Yetimalar, Y	1
Gürgör, N	1
Başoğlu, M	1
Hsu, C	1
Sliwa, JA	1
Sarrigiannis, P	1
Tsakanicas, C	1
Anagnostouli, M	1
Karandreas, N	1
Solaro, C	5
Brichetto, G	1
Battaglia, MA	1
Messmer Uccelli, M	2
Mancardi, GL	5
Shery, T	1
Proudlock, FA	1
Sarvananthan, N	2
McLean, RJ	1
Choudhuri, I	1
Mueller, ME	1
Gruenthal, M	1
Olson, WL	1
Olson, WH	1
Samkoff, LM	1
Daras, M	1
Tuchman, AJ	1
Koppel, BS	1
Houtchens, MK	1
Richert, JR	1
Sami, A	1
Rose, JW	1
Lunardi, GL	1
Capello, E	1
Inglese, M	1
Uccelli, A	2
Khan, OA	1
Uccelli, MM	2
Cutter, NC	1
Scott, DD	1
Johnson, JC	1
Whiteneck, G	1
Guglieri, P	1
Bandini, F	1
Castello, E	1
Mazzella, L	1
Stahl, JS	1
Rottach, KG	1
Averbuch-Heller, L	1
von Maydell, RD	1
Collins, SD	1
Schapiro, RT	1

Studies

Bobenko, AI

Heller, S

Schmitt, N

Cherdtrakulkiat, R

Lawung, R

Nabu, S

Tantimavanich, S

Sinthupoom, N

Prachayasittikul, S

Prachayasittikul, V

Zhang, B

Wu, C

Zhang, Z

Yan, K

Li, C

Li, Y

Li, L

Zheng, C

Xiao, Y

He, D

Zhao, F

Su, JF

Lun, SM

Hou, YJ

Duan, LJ

Wang, NC

Shen, FF

Zhang, YW

Gao, ZW

Li, J

Du, XJ

Zhou, FY

Yin, Z

Zhu, J

Yan, D

Lou, H

Yu, H

Feng, C

Wang, Z

Wang, Y

Hu, X

Li, Z

Shen, Y

Hu, D

Chen, H

Wu, X

Duan, Y

Zhi, D

Zou, M

Zhao, Z

Zhang, X

Yang, X

Zhang, J

Wang, H

Popović, KJ

Popović, DJ

Miljković, D

Lalošević, D

Čapo, I

Popović, JK

Liu, M

Song, H

Xing, Z

Lu, G

Chen, D

Valentini, AM

Di Pinto, F

Coletta, S

Guerra, V

Armentano, R

Caruso, ML

Gong, J

Wang, N

Bian, L

Wang, M

Ye, M

Wen, N

Fu, M

Fan, W

Meng, Y

Dong, G

Lin, XH

Liu, HH

Gao, DM

Cui, JF

Ren, ZG

Chen, RX

Önal, B

Özen, D

Demir, B

Akkan, AG

Özyazgan, S

Payette, G

Geoffroy, V

Martineau, C

Villemur, R

Jameel, T

Baig, M

Gazzaz, ZJ

Tashkandi, JM

Al Alhareth, NS

Khan, SA

Butt, NS

Wang, J

Geng, Y

Zhang, Y

Wang, X

Liu, J

Basit, A

Miao, T

Liu, W

Jiang, W

Yu, ZY

Wu, L

Qu, B

Sun, JX

Cai, AL

Xie, LM

Groeneveld, J

Ho, SL

Mackensen, A

Mohtadi, M

Laepple, T

Genovesi, S

Nava, E

Bartolucci, C

Severi, S

Vincenti, A

Contaldo, G

Bigatti, G

Ciurlino, D

Bertoli, SV

Slovak, JE

Hwang, JK

Rivera, SM

Villarino, NF

Li, S

Cao, G

Ling, M

Ji, J

Zhao, D

Sha, Y

Gao, X

Liang, C

Guo, Q

Zhou, C

Ma, Z

Xu, J

Wang, C

Zhao, W

Xia, X

Jiang, Y

Peng, J

Jia, Z

Li, F

Chen, X

Mo, J

Zhang, S

Li, X

Huang, T

Zhu, Q

Wang, S

Ge, RS

Fortunato, G

Lin, J

Agarwal, PK

Kohen, A

Singh, P

Cheatum, CM

Zhu, D

Hayman, A

Kebede, B

Stewart, I

Chen, G

Frew, R

Guo, X

Gong, Q

Borowiec, J

Han, S

Zhang, M

Willis, M

Kreouzis, T

Yu, K

Chirvony, VS

Sekerbayev, KS

Pérez-Del-Rey, D

Martínez-Pastor, JP

Palazon, F

Boix, PP

Taurbayev, TI

Sessolo, M

Bolink, HJ

Lu, M

Lan, Y

Xiao, J

Song, M

Chen, C

Huang, Q

Cao, Y

Ho, CT

Qi, B

Wang, Q

Zhang, W

Fang, L

Xie, CL

Chen, R

Yang, S

Xia, JM

Zhang, GY

Chen, CH

Yang, XW

Domenech-Ximenos, B

Garza, MS

Prat-González, S

Sepúlveda-Martínez, Á

Crispi, F

Perea, RJ

Garcia-Alvarez, A

Sitges, M

Kalumpha, M

Guyo, U

Zinyama, NP

Vakira, FM

Nyamunda, BC

Varga, M

Drácz, L

Kolbenheyer, E

Varga, F

Patai, ÁV

Solymosi, N

Patai, Á

Kiss, J

Gaál, V

Nyul, Z

Mosdósi, B

Valdez, M

Moosavi, L

Heidari, A

Novakovic-Agopian, T

Kornblith, E

Abrams, G

McQuaid, JR

Posecion, L

Burciaga, J

D'Esposito, M

Chen, AJW

Samy El Gendy, NM

Wesolowska, P

Georg, D

Lechner, W

Kazantsev, P

Bokulic, T

Tedgren, AC

Adolfsson, E

Campos, AM

Alves, VGL

Suming, L

Hao, W

Ekendahl, D

Koniarova, I

Bulski, W

Chelminski, K

Samper, JLA

Vinatha, SP

Rakshit, S

Siri, S

Tomsejm, M

Tenhunen, M

Povall, J

Kry, SF

Followill, DS

Thwaites, DI

Izewska, J

Kang, JH

Yoon, Y

Song, J

Van de Winckel, A

Gauthier, L

Chao, CT

Lee, YH

Li, CM

Han, DS

Huang, JW

Huang, KC

Ni, L

Güttinger, R

Triana, CA

Spingler, B

Baldridge, KK

Patzke, GR

Shen, X

Wang, B

Xie, S

Deng, W

Wu, D

Zhang, Q

Voskamp, BJ

Peelen, MJCS

Ravelli, ACJ

van der Lee, R

Mol, BWJ

Pajkrt, E

Ganzevoort, W

Kazemier, BM

Tibrewala, R

Bahroos, E

Mehrabian, H

Foreman, SC

Link, TM

Pedoia, V

Majumdar, S

Jablonski, CL

Leonard, C

Salo, P

Krawetz, RJ

Yoon, N

Hong, SN

Cho, JG

Jeong, HK

Lee, KH

Park, HW

Barman, S

Konai, MM

Samaddar, S

Haldar, J

Mohamed, HSH

Li, CF

Hu, ZY

Deng, Z

Chen, LH

Su, BL

Chu, K

Liu, YP

Li, YB

Zhang, H

Xu, C

Zou, Z

Wu, Z

Xia, Y

Zhao, P

Wang, HT

de Biase, S

Pellitteri, G

Gigli, GL

Valente, M

Comi, G

Solari, A

Leocani, L

Centonze, D

Otero-Romero, S

Redon, S

Graillon, N

Régis, J

Donnet, A

Khan, N

Woodruff, TM

Smith, MT

Trojano, M

Sastre-Garriga, J

Hartung, HP

Soelberg Sørensen, P

Thompson, AJ

Vermersch, P

Gold, R

Montalban, X

Starck, M

Albrecht, H

Pöllmann, W

Dieterich, M

Straube, A

Bittner, S

Höhn, K

Göbel, K

Kleinschnitz, C

Wiendl, H

Meuth, SG

Shaikh, AG

Thurtell, MJ

Optican, LM

Leigh, RJ

Heinzlef, O

Monteil-Roch, I

Jain, S

Proudlock, F

Constantinescu, CS

Gottlob, I

Fabre, K

Smet-Dieleman, H

Zeyen, T

Yetimalar, Y

Gürgör, N

Başoğlu, M

Hsu, C

Sliwa, JA

Sarrigiannis, P

Tsakanicas, C

Anagnostouli, M

Karandreas, N

Solaro, C

Brichetto, G

Battaglia, MA

Messmer Uccelli, M

Mancardi, GL

Shery, T

Proudlock, FA

Sarvananthan, N

McLean, RJ

Choudhuri, I

Mueller, ME

Gruenthal, M

Olson, WL

Olson, WH

Samkoff, LM

Daras, M

Tuchman, AJ

Koppel, BS

Houtchens, MK

Richert, JR

Sami, A

Rose, JW

Lunardi, GL

Capello, E

Inglese, M

Uccelli, A

Khan, OA

Uccelli, MM

Cutter, NC

Scott, DD

Johnson, JC

Whiteneck, G

Guglieri, P

Bandini, F

Castello, E

Mazzella, L

Stahl, JS

Rottach, KG

Averbuch-Heller, L

von Maydell, RD

Collins, SD

Schapiro, RT

Clinical Trials (2)

Trial Overview

Trial	Enrollment	Study Type	Start Date	Status
The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595]	36 participants (Anticipated)	Interventional	2023-05-18	Recruiting
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]	8 participants (Actual)	Interventional	2009-11-30	Terminated (stopped due to PI left institution)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595]

36 participants (Anticipated)

Interventional

2023-05-18

Recruiting

Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]

8 participants (Actual)

Interventional

2009-11-30

Terminated (stopped due to PI left institution)

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for gabapentin and MS (Multiple Sclerosis)

Article	Year
Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227 Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P	2019
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:11 Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze	2016
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications]. Der Nervenarzt, 2011, Volume: 82, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor	2011
[Pharmacological treatment of spasticity in multiple sclerosis]. Revue neurologique, 2012, Volume: 168 Suppl 3 Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant	2012
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3 Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin	2001

Article

Year

Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:11

Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze

2016

[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].

Der Nervenarzt, 2011, Volume: 82, Issue:10

Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor

2011

[Pharmacological treatment of spasticity in multiple sclerosis].

Revue neurologique, 2012, Volume: 168 Suppl 3

Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant

2012

Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.

Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3

Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin

2001

Trials

7 trials available for gabapentin and MS (Multiple Sclerosis)

Article	Year
Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. Journal of neurology, 2010, Volume: 257, Issue:3 Topics: Adult; Amines; Brain Stem; Clinical Protocols; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose	2010
Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis. Acta neurologica Scandinavica, 2004, Volume: 109, Issue:6 Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami	2004
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Archives of physical medicine and rehabilitation, 1997, Volume: 78, Issue:5 Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid	1997
Open label gabapentin treatment for pain in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 1997, Volume: 3, Issue:4 Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab	1997
Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Archives of physical medicine and rehabilitation, 2000, Volume: 81, Issue:2 Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cross-Over Studies; C	2000
Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2000, Volume: 6, Issue:3 Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma-	2000
Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis? Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 71, Issue:1 Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Electrooculography; Female; Gabapentin; gamma-	2001

Article

Year

Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin.

Journal of neurology, 2010, Volume: 257, Issue:3

Topics: Adult; Amines; Brain Stem; Clinical Protocols; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose

2010

Clinical efficacy of gabapentin for paroxysmal symptoms in multiple sclerosis.

Acta neurologica Scandinavica, 2004, Volume: 109, Issue:6

Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami

2004

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.

Archives of physical medicine and rehabilitation, 1997, Volume: 78, Issue:5

Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid

1997

Open label gabapentin treatment for pain in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England), 1997, Volume: 3, Issue:4

Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab

1997

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.

Archives of physical medicine and rehabilitation, 2000, Volume: 81, Issue:2

Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cross-Over Studies; C

2000

Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England), 2000, Volume: 6, Issue:3

Topics: Acetates; Amines; Anticonvulsants; Circadian Rhythm; Cyclohexanecarboxylic Acids; Gabapentin; gamma-

2000

Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?

Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 71, Issue:1

Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Electrooculography; Female; Gabapentin; gamma-

2001

Other Studies

17 other studies available for gabapentin and MS (Multiple Sclerosis)

Article	Year
Italian consensus on treatment of spasticity in multiple sclerosis. European journal of neurology, 2020, Volume: 27, Issue:3 Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections	2020
First Bite Syndrome After Trigeminal Radiosurgery: Case Report and Pathophysiology. Headache, 2018, Volume: 58, Issue:10 Topics: Adult; Carbamazepine; Cheek; Combined Modality Therapy; Drug Therapy, Combination; Facial Muscles; F	2018
Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. Pharmacology, biochemistry, and behavior, 2014, Volume: 126 Topics: Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclohexanecarboxyli	2014
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms. European neurology, 2016, Volume: 75 Suppl 1 Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli	2016
Pharmacological tests of hypotheses for acquired pendular nystagmus. Annals of the New York Academy of Sciences, 2011, Volume: 1233 Topics: Amines; Baclofen; Cerebellar Cortex; Cyclohexanecarboxylic Acids; Eye Movements; Gabapentin; gamma-A	2011
Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. American journal of ophthalmology, 2002, Volume: 134, Issue:5 Topics: Acetates; Adult; Amines; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Diplopia; Excitator	2002
Improvement of acquired pendular nystagmus by gabapentin: case report. Bulletin de la Societe belge d'ophtalmologie, 2001, Issue:282 Topics: Acetates; Administration, Oral; Amines; Baclofen; Cyclohexanecarboxylic Acids; Female; Gabapentin; g	2001
Phantom breast pain as a source of functional loss. American journal of physical medicine & rehabilitation, 2004, Volume: 83, Issue:8 Topics: Acetates; Activities of Daily Living; Amines; Anti-Anxiety Agents; Breast Neoplasms; Carcinoma in Si	2004
Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study. Neurophysiologie clinique = Clinical neurophysiology, 2004, Volume: 34, Issue:3-4 Topics: Adult; Amines; Baclofen; Blinking; Brain; Clonazepam; Cyclohexanecarboxylic Acids; Electromyography;	2004
Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2005, Volume: 25, Issue:6 Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Follow-Up Studies;	2005
The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. The British journal of ophthalmology, 2006, Volume: 90, Issue:7 Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gab	2006
Survey of management of acquired nystagmus in the United Kingdom. Eye (London, England), 2007, Volume: 21, Issue:9 Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists;	2007
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology, 1997, Volume: 49, Issue:1 Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut	1997
An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology, 1998, Volume: 51, Issue:2 Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami	1998
Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology, 1998, Volume: 51, Issue:2 Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut	1998
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset. European journal of neurology, 1999, Volume: 6, Issue:4 Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis	1999
A pilot study of gabapentin as treatment for acquired nystagmus. Neuro-ophthalmology (Aeolus Press), 1996, Volume: 16, Issue:2 Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Stem; Cerebrovascular Disorders; Cyclohexanecarboxyl	1996

Article

Year

Italian consensus on treatment of spasticity in multiple sclerosis.

European journal of neurology, 2020, Volume: 27, Issue:3

Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections

2020

First Bite Syndrome After Trigeminal Radiosurgery: Case Report and Pathophysiology.

Headache, 2018, Volume: 58, Issue:10

Topics: Adult; Carbamazepine; Cheek; Combined Modality Therapy; Drug Therapy, Combination; Facial Muscles; F

2018

Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.

Pharmacology, biochemistry, and behavior, 2014, Volume: 126

Topics: Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclohexanecarboxyli

2014

THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.

European neurology, 2016, Volume: 75 Suppl 1

Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli

2016

Pharmacological tests of hypotheses for acquired pendular nystagmus.

Annals of the New York Academy of Sciences, 2011, Volume: 1233

Topics: Amines; Baclofen; Cerebellar Cortex; Cyclohexanecarboxylic Acids; Eye Movements; Gabapentin; gamma-A

2011

Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis.

American journal of ophthalmology, 2002, Volume: 134, Issue:5

Topics: Acetates; Adult; Amines; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Diplopia; Excitator

2002

Improvement of acquired pendular nystagmus by gabapentin: case report.

Bulletin de la Societe belge d'ophtalmologie, 2001, Issue:282

Topics: Acetates; Administration, Oral; Amines; Baclofen; Cyclohexanecarboxylic Acids; Female; Gabapentin; g

2001

Phantom breast pain as a source of functional loss.

American journal of physical medicine & rehabilitation, 2004, Volume: 83, Issue:8

Topics: Acetates; Activities of Daily Living; Amines; Anti-Anxiety Agents; Breast Neoplasms; Carcinoma in Si

2004

Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study.

Neurophysiologie clinique = Clinical neurophysiology, 2004, Volume: 34, Issue:3-4

Topics: Adult; Amines; Baclofen; Blinking; Brain; Clonazepam; Cyclohexanecarboxylic Acids; Electromyography;

2004

Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2005, Volume: 25, Issue:6

Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Follow-Up Studies;

2005

The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study.

The British journal of ophthalmology, 2006, Volume: 90, Issue:7

Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gab

2006

Survey of management of acquired nystagmus in the United Kingdom.

Eye (London, England), 2007, Volume: 21, Issue:9

Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists;

2007

Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin.

Neurology, 1997, Volume: 49, Issue:1

Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut

1997

An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.

Neurology, 1998, Volume: 51, Issue:2

Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami

1998

Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients.

Neurology, 1998, Volume: 51, Issue:2

Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut

1998

A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset.

European journal of neurology, 1999, Volume: 6, Issue:4

Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis

1999

A pilot study of gabapentin as treatment for acquired nystagmus.

Neuro-ophthalmology (Aeolus Press), 1996, Volume: 16, Issue:2

Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Stem; Cerebrovascular Disorders; Cyclohexanecarboxyl

1996